IP Library › Granted Patent US 12,631,642
Granted Patent B2
US 12,631,642 · App. 16/962,352 · Granted May 19, 2026

Renal cancer detection method and test drug

Inventors: Noriaki Arakawa (Yokohama, JP); Hisashi Hirano (Yokohama, JP); Noboru Nakaigawa (Yokohama, JP); Masahiro Yao (Yokohama, JP); Norihisa Ohtake (Yokohama, JP)
Assignees: PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY; TOSOH CORPORATION
G01N33/57525G01N33/68G01N33/6848
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,631,642
App. No.
16/962,352
Granted
May 19, 2026
Kind
B2
Abstract

An object of the present invention is to provide a method for detecting renal cancer, and a reagent that can be used for the method. Provided is a method for detecting renal cancer, which includes measuring the amount of TFPI2 in a sample derived from a patient. An antibody that specifically recognizes NT-TFPI2 and intact TFPI2 is included in a detection reagent for renal cancer.

Claims (11)

1 . A method of detecting and treating renal cancer in a subject, said method comprising:

measuring the amount of tissue factor pathway inhibitor 2 (TFPI2) in a sample from the subject,

detecting the subject having renal cancer when said measured amount of TFPI2 exceeds a predetermined standard value, and

treating the subject detected with the renal cancer with a method for the treatment of the renal cancer selected from the group consisting of surgical resection, drug therapy, and radiation therapy,

wherein the subject is a subject with suspected renal cancer or a subject under follow-up after definitive diagnosis of renal cancer,

wherein the standard value is a measured value showing optimum sensitivity and specificity by measuring healthy individuals and renal cancers and analyzing receiver operating characteristic (ROC) curve,

wherein the sample is serum or plasma, and

the drug for the drug therapy is selected from the group consisting of tyrosine kinase inhibitors, mTOR inhibitors, and immune checkpoint inhibitors.

2 . The method according to claim 1 , wherein said amount of TFPI2 is the sum of the amount of TFPI2 processing polypeptide and the amount of intact TFPI2.

3 . The method according to claim 1 , wherein measurement is carried out using mass spectrometry.

4 . The method according to claim 1 , wherein the standard value is 219 pg/mL in the case of plasma and 189 pg/mL or 200 pg/mL in the case of serum.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 15, 2020
From: ARAKAWA, NORIAKI; HIRANO, HISASHI; NAKAIGAWA, NOBORU; YAO, MASAHIRO; OHTAKE, NORIHISA
To: PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY; TOSOH CORPORATION
Reel/Frame 053217/0528 →
Priority Claims (1)
JP 2018-004737 · Jan 16, 2018 · national
Continuity (1)
Related Publication 20210063400A1 · Mar 4, 2021
References Cited (37)
US 11193936B2 · Arakawa · 2021 [cited by examiner]
US 20130203619A1 · Copland, III · 2013 [cited by examiner]
US 20140295456A1 · Blonder et al. · 2014 [cited by applicant]
US 20170322218A1 · Arakawa et al. · 2017 [cited by applicant]
US 20230221322A1 · Shibata · 2023 [cited by examiner]
CN 107723368A · 2018 [cited by applicant]
JP 5224309B2 · 2013 [cited by applicant]
JP 6074676B2 · 2017 [cited by applicant]
WO 2016084912A1 · 2016 [cited by applicant]
Bin Gu, Qiang Ding, Zujun Fang, Cuowei Xia, Expression and methylation status of tissue factor pathway inhibitor-2 in renal cell carcinoma, 2008, Chinese Journal of Urology, 12:12-15 (Year: 2008). [cited by examiner]
The Human Protein Atlas, Expression of TFPI2 in Cancer, Retrieved from the Internet https://web.archive.org/web/20170826002830/http://www.proteinatlas.org/ENSG00000105825-TFPI2/pathology#gene_information: Aug. 2017,2 pa… [cited by examiner]
Vallejo, D. D., Rojas Ra{acute over (m)}irez, C., Parson, K. F., Han, Y., Gadkari, V. V., & Ruotolo, B. T., Mass Spectrometry Methods for Measuring Protein Stability, 2022, Chemical Reviews, 122(8), 7690-7719. (Year: 20… [cited by examiner]
Kapingidza, A.B., Kowal, K., Chruszcz, M, Antigen-Antibody Complexes, 2020, Vertebrate and Invertebrate Respiratory Proteins, Lipoproteins and other Body Fluid Proteins. Subcellular Biochemistry, vol. 94:(465-497) (Year… [cited by examiner]
The Human Protein Atlas, TFPI2 Antibodies, Retrieved from the Internet: https://web.archive.org/web/20220826125447/https://www.proteinatlas.org/ENSG00000105825-TFP12/antibody :Aug. 2022, 2 pages (Year: 2022). [cited by examiner]
Quintero-Ronderos, P., Arango, M. T., Castiblanco, J., Correa, N. E., & Montoya-Ortiz, G. Analysis of proteins and antibodies. (2013). El Rosario University Press. Chapter 48 (793-811) https://www.ncbi.nlm.nih.gov/books… [cited by examiner]
Almagro, J. C., & Fransson, J. (2008). Humanization of antibodies. Frontiers in bioscience : a journal and virtual library, 13, 1619-1633. (Year: 2008). [cited by examiner]
Cook, G. (2000). Immunobiology: The Immune System in Health and Disease (4th edn) by CA Janeway, P. Travers, M. Walport and JD Capra. Immunology today, 21(4), 201 (Year: 2000). [cited by examiner]
Edwards, B. M., Barash, S. C., Main, S. H., Choi, G. H., Minter, R., Ullrich, S., . . . & Vaughan, T. J. (2003). The remarkable flexibility of the human antibody repertoire; isolation of over one thousand different anti… [cited by examiner]
Lloyd, C., Lowe, D., Edwards, B., Welsh, F., Dilks, T., Hardman, C., & Vaughan, T. (2009). Modelling the human immune response: performance of a 1011 human antibody repertoire against a broad panel of therapeutically re… [cited by examiner]
Brown, M., Rittenburg, M. B., Chen, C., & Roberts, V. A. (1996). Tolerance of single, but not multiple, amino acid replacements in antibody VH CDR 2: a means of minimizing B cell wastage from somatic hypermutation?. Jou… [cited by examiner]
Vajdos, F. F., Adams, C. W., Breece, T. N., Presta, L. G., de Vos, A. M., & Sidhu, S. S. (2002). Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagen… [cited by examiner]
Wojtukiewicz, M. Z., Sierko, E., Zimnoch, L., Kozlowski, L., & Kisiel, W. (2003). Immunohistochemical localization of tissue factor pathway inhibitor-2 in human tumor tissue. Thrombosis and haemostasis, 90(07), 140-146.… [cited by examiner]
The Human Protein Atlas, Expression of TFPI2 in Cancer, Retrieved from the Internet https://web.archive.org/web/20170826002830/http://www.proteinatlas.org/ENSG00000105825-TFPI2/pathology#gene_information: Aug. 2017,2 pa… [cited by examiner]
Arakawa, N., Kobayashi, H., Yonemoto, N., Masuishi, Y., Ino, Y., Shigetomi, H., . . . & Miyagi, E. (2016). Clinical significance of tissue factor pathway inhibitor 2, a serum biomarker candidate for ovarian clear cell c… [cited by examiner]
Goel et al. Plasticity within the Antigen-Combining Site May Manifest as Molecular Mimicry in the Humoral Immune Response. J Immunol (2004) 173 (12): 7358-7367. (Year: 2004). [cited by examiner]
Kapingidza et al. Antigen-Antibody Complexes. Subcellular Biochemistry, Springer Nature Switzerland AG, Gewerbestrasse, 11, 6300 Cham, Switzerland, 2020, vol. 94, pp. 465-497. (Year: 2020). [cited by examiner]
Schmid et al. Sunitinib in the treatment of metastatic renal cell carcinoma. Therapeutic Advances in Urology, 2016, vol. 8(6) 348-371. (Year: 2016). [cited by examiner]
Extended European Search Report dated Jul. 28, 2021 from the European Patent Office in counterpart Application No. 18901702.3. [cited by applicant]
The Human Protein Atlas, Aug. 26, 2017, Retrieved from the Internet: URL: https://www.proteinatlas.org/ENSG00000105825-TFPI2/pathology, 2 pages total. [cited by applicant]
Marek Z. Wojtukiewicz et al., “Immunohistochemical localization of tissue factor pathway inhibitor-2 in human tumor tissue”, Thrombosis and Haemostasis, Cellular Proteolysis and Oncology, 2003, vol. 90, pp. 140-146 (7 p… [cited by applicant]
Noriaki Arakawa et al., “Secretome-Based Identification of TFPI2, A Novel Serum Biomarker for Detection of Ovarian Clear Cell Adenocarcinoma”, Journal of Proteome Research, 2013, pp. 4340-4350, vol. 12. [cited by applicant]
Noriaki Arakawa et al, “Clinical Significance of Tissue Factor Pathway Inhibitor 2, a Serum Biomarker Candidate for Ovarian Clear Cell Carcinoma”, PLOS ONE 11(10), 2016, pp. 1-17. [cited by applicant]
Bin Gu et al., “EGCG inhibits growth and induces apoptosis in renal cell carcinoma through TFPI-2 overexpression”, Oncology Reports, Mar. 2009, pp. 635-640, vol. 21, No. 3. [cited by applicant]
Bin Gu et al. “Expression and methylation status of tissue factor pathway inhititor-2 in renal cell carcinoma”, Chinese Journal of Urology, 2008, pp. 12-15. [cited by applicant]
International Search Report for PCT/JP2018/047882 mailed on Mar. 19, 2019. [cited by applicant]
Office Action issued May 9, 2023 by Japan Patent Office in Japanese Application No. 2019-566393. [cited by applicant]
Noriaki Arakawa et al., “Cell Culture-based Biomarker Discovery and Clinical Applications”, Proteome Letters, 2016, vol. 1, pp. 81-87 (7 pages total). [cited by applicant]